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Background: To evaluate the clinical and oncological outcomes and to identify prognostic factors for survival in
Chinese patients with renal cell carcinoma (RCC) and venous tumor thrombus (VTT).
Methods: A total of 86 patients who underwent nephrectomy and tumor thrombectomy for RCC and venous tumor
thrombus extension from 2003 to 2013 were included in this retrospective study. The records of these patients were
reviewed. Kaplan-Meier analysis was used to determine cancer-specific survival (CSS). Prognostic factors for CSS were
identified by univariate and multivariate analyses using the Cox proportional hazards regression mode.
Results: All patients in this cohort received radical nephrectomy and tumor thrombectomy. Median follow-up period
was 27.0 months (range 3–111). No patients died intraoperatively, and the complication rate was 36.0%. The 1-, 3-, and
5-year CSS rates for all patients were 93.0%, 70.9%, and 58.1%, respectively, and those for patients without distant
metastasis at presentation were 95.3%, 82.6%, and 68.6%, respectively. Multivariate Cox regression analysis showed
that lymph node invasion, distant metastasis at presentation, and invasion of the inferior vena cava (IVC) wall were
the independent prognostic factors for CSS in all patients. For patients without distant metastasis, tumor grade, lymph
node invasion, and perinephric fat invasion were significantly associated with CSS on multivariate analysis.
Conclusions: Survival rates for patients with RCC and VTT were still poor. Our results indicated that lymph node
invasion, distant metastasis at presentation, and invasion of the IVC wall were independent negative prognostic factors.
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Renal cell carcinoma is a common solid tumor of the
urinary system, and its incidence tends to rise year by
year. It has been reported that approximately 4%–15%
patients with renal cell carcinoma (RCC) were found to
have venous tumor thrombus on diagnosis of the cancer
[1]. Despite advances in targeted molecular therapy,
radiotherapy, chemotherapy, and immunotherapy, surgical
treatment is still the most important factor influencing the
prognosis of patients with RCC [2]. With continuous
improvements in surgical techniques and perioperative
management, surgical morbidity and mortality rates are* Correspondence: wubin81688880@sina.com
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unless otherwise stated.increasingly favorable in patients with RCC and venous
tumor thrombus (VTT). On the other hand, the 5-year
cancer-specific survival (CSS) is a mere 25%–65% in those
patients with RCC and VTT following surgery [3-5].
Some prognostic factors have been reported in patients
with RCC and VTT, mostly by retrospective studies based
on small-sample sizes. However, the significance of these
factors remains controversial. Some researchers have
concluded that the level of venous tumor thrombus
correlates negatively with prognosis [6], but others
have held that the level of venous tumor thrombus is not
an independent prognosis predictor [3,5]. Although there
have been successful cases in which neoadjuvant-targeted
molecular therapies have succeeded in lowering the level
of tumor thrombus, making surgical treatment possiblehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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patients with Level III and IV tumor thrombus remains
controversial [8]. Most studies on the prognosis (and its
influencing factors) of patients with RCC and VTT have
been conducted in Western countries, and there have
been only a few studies conducted in Asian populations
[3,9], in particular in Chinese populations [10]. In the
present study, therefore, we retrospectively analyzed the
clinicopathological data of patients with RCC and VTT
who underwent surgical treatment at our center and
assessed the effect and significance of each prognostic
factor on these patients.
Methods
From June 2003 to June 2013, 1,518 patients were diag-
nosed with RCC in our institution. Among these, a total of
91 patients underwent nephrectomy and tumor thrombec-
tomy for RCC and VTT extension. Five patients were lost
at follow-up, and 86 patients were included in this study.
Those patients who were inoperable were not included in
this study. The medical records were reviewed retrospect-
ively for demographics, clinical symptoms at diagnosis,
laboratory findings, performance status (PS) as defined by
the Eastern Cooperative Oncology Group (ECOG] [11],
and clinical tumor features including tumor size,
tumor laterality, and maximal level of tumor thrombus.
Histopathological features included tumor-node-metastasis
(TNM) stage (according to the newly-revised 2009 AJCC
TNM classification), histopathological subtypes, tumor
grading (according to the 2012 International Society of
Urological Pathology (ISUP) grading system) [12], invasion
of renal pelvis, invasion of venous wall, and perinephric fat
invasion. Informed consent for this study was obtained
from each patient, and the study was approved by the
Research Ethics Committee of our institution.
All patients preoperatively underwent routine blood
tests, chest X-ray (computed tomography (CT) for selected
patients), abdominal CT, ultrasound, and/or abdominal
magnetic resonance imaging (MRI), and/or bone scanning.
Postoperative follow-up included blood tests, chest and
abdominal CT examination, and/or bone scanning,
and/or brain MRI. The follow-up data was obtained
during checkup visits and telephone interviews. The
maximal level of tumor thrombus was classified according
to the Mayo Clinical Classification [13]: level 0, thrombus
extending to the renal vein; level I, tumor thrombus
present either at the entry of the renal vein or within the
inferior vena cava (IVC) <2 cm from the confluence of the
renal vein and IVC; level II, tumor thrombus extending
within the IVC >2 cm above the confluence of the renal
vein and IVC but still remaining below the hepatic vein;
level III, tumor thrombus involving the intrahepatic
IVC; and level IV, tumor thrombus extending above the
diaphragm or into the right atrium.Surgery
None of the patients with level IV tumor thrombus
received surgical therapy in our institution. However,
two patients demonstrated clinical thrombus regression
from level IV to III after receiving targeted molecular
therapies (2–3 cycles), and both of them then received
surgical therapy. All patients enrolled in this study
underwent radical nephrectomy and thrombectomy. The
surgical approach was determined by the characteristics
of the tumor and associated thrombus, as well as the
experience of the surgeons. Twelve (14.0%) patients with
complications of invasion of the IVC wall were detected,
and all of these underwent partial resection of the IVC
wall. Two of them needed reconstruction of the IVC
with synthetic grafts due to the extensive IVC defect.
Statistic analysis
The CSS was calculated using the Kaplan-Meier method,
and the differences were determined by the log-rank test.
The CSS was evaluated from the date of surgery to the last
follow-up or death caused by RCC. Prognostic factors for
CSS were identified by univariate and multivariate analyses
using the Cox proportional hazards regression model, and
hazard ratio (HR) with 95% confidence intervals were
calculated. Differences were considered statistically signifi-
cant at a P value of <0.05. All statistical analyses were
performed using the SPSS software (version 22.0).
Results
A total of 86 patients with RCC and VTT extension
were included in this retrospective study. Baseline
clinicopathological characteristics of the patients are
summarized in Table 1. Male-to-female ratio was 2:1.
A total of 47 cases (54.7%) of RCC occurred on the
right side, and 39 cases (45.3%) occurred on the left. The
mean age at diagnosis was 57.7 ± 11.3 years (range 15–79).
The mean diameter of tumor was 8.2 ± 2.4 cm (range
3.2–14.0). The median follow-up period was 27.0 months
(range 3–111). A total of 53 patients (61.6%) had a level 0
tumor thrombus, 16 (18.6%) had a level I thrombus, 11
(12.8%) had a level II thrombus, and 6 (7%) had a level III
thrombus according to the Mayo Clinical Classification.
Fifty patients (58.1%) were T3a stage, 17 (19.8%) were
T3b, 10 (11.6%) were T3c, and 9 (10.5%) were T4 according
to the newly revised 2009 AJCC TNM classification. The
tumor was symptomatic in 47 cases (54.7%), whereas 39
cases (45.3%) were incidental findings. Thirty-one (36%)
patients had perinephric fat invasion and ten (11.6%) had
renal pelvis invasion. Pathology results showed that clear
cell RCC was diagnosed in 67 (77.9%) patients and
non-clear-cell subtypes in 19 (22.1%) patients.
All patients in this cohort received radical nephrectomy
and tumor thrombectomy. The mean duration of surgery
was 3.6 ± 1.1 h (range 1.4–6.1), and 51 patients received
Table 1 Clinical and histopathological characteristics
of patients





N (%) 86 53(61.6) 33(38.4)
Age, year 57.7 ± 11.3 57.1 ± 11.5 58.7 ± 11.2 0.535
Gender (%)
Male 58(67.4) 35(66) 23(69.7) 0.725
Female 28(32.6) 18(34) 10(30.3)
Laterality (%)
Left 39(45.3) 27(50.9) 12(36.4) 0.187
Right 47(54.7) 26(49.1) 21(63.6)
Clinical symptom (%)
Yes 47(54.7) 26(49.1) 21(63.6) 0.187
No 39(45.3) 27(50.9) 12(36.4)
Tumor size, cm 8.2 ± 2.4 8.1 ± 2.2 8.3 ± 2.5 0.731
ECOG-PS 0.8 ± 0.8 0.6 ± 0.8 1.2 ± 0.7 0.04
Histological type (%)
Clear cell 67(77.9) 43(81.1) 24(72.7) 0.361
Others 19(22.1) 10(18.9) 9(27.3)
Tumor grade (%)
G1 6(7.0) 6(11.3) 0(0)
G2 38(44.2) 24(45.3) 14(42.4) 0.156
G3 33(38.4) 19(35.8) 14(42.4)
G4 9(10.5) 4(7.5) 5(15.2)
T stage (%)
T3a 50(58.1) 49(92.5) 0(0)
T3b 17(19.8) 0(0) 18(54.5) 0.000
T3c 10(11.6) 0(0) 10(30.3)
T4 9(10.5) 4(7.5) 5(15.2)
N stage (%)
N0 or Nx 70(81.4) 45(84.9) 25(75.8) 0.289
N1 16(18.6) 8(15.1) 8(24.2)
M stage (%)
M0 75(87.2) 50(94.3) 25(75.8) 0.029
M1 11(12.8) 3(5.7) 8(24.2)
Perinephric fat
invasion (%)
Yes 31(36.0) 11(20.8) 20(60.6) 0.000
No 55(64.0) 42(79.2) 13(39.4)
Renal pelvis invasion (%)
Yes 10(11.6) 5(9.4) 5(15.2) 0.647
No 76(88.4) 48(90.6) 28(84.8)
Thrombus level (%)
Renal vein 53(61.6) 53(100) 0(0)
I 16(18.6) 0(0) 16(48.5) 0.000
Table 1 Clinical and histopathological characteristics
of patients (Continued)
II 11(12.8) 0(0) 11(33.3)
III 6(7.0) 0(0) 6(18.2)
Invasion of IVC wall (%)
Yes 12(14.0) 0(0) 12(36.4) 0.000
No 74(86.0) 53(100) 21(63.6)
Neoadjuvant-molecular-
targeted therapy (%)
Yes 2(2.3) 0(0) 2(6.1) 0.144
No 84(97.7) 53(100) 31(93.9)
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units. No patient died intraoperatively. The complication
rate was 36.0%, but major complications occurred only in
13 (15.1%) patients, including pulmonary embolism in one,
acute renal insufficiency in six, ileus in two, re-exploration
due to acute postoperative hemorrhage in two, acute
myocardial infarction in one, and heart failure in one.
An 80-year-old patient with left renal cell carcinoma
and level III tumor thrombus underwent extracorporeal
circulation. Due to the presence of preoperative renal
insufficiency and anemia in this aged patient, we opted
not to clamp the right renal vein intraoperatively with the
assistance of extracorporeal circulation. There was no
decline in renal function after radical nephrectomy and
tumor thrombectomy in this patient. After a 32-month
recurrence-free survival, right adrenal metastasis was
observed. The patient then received tyrosine kinase
inhibitors as treatment; thus far, the overall survival
time for this patient has been 46 months.
A total of 71 (82.6%) patients received cytokine therapy
postoperatively, usually with interferon-α 3 million IU
3 days per week for 3 months or combining it with
low-dose interleukin-2. The most common site of metasta-
sis was the lung, followed by bones and liver. A total of 12
patients who were observed to have local recurrence or
distant metastasis postoperatively received tyrosine kinase
inhibitors (including sunitinib and sorafenib). The 1-, 3-,
and 5-year CSS rates for all patients were 93.0%, 70.9%, and
58.1%, respectively (Figure 1A). The 1-, 3-, and 5-year CSS
rates for patients without distant metastasis at presentation
were 95.3%, 82.6%, and 68.6%, respectively. We found that
the CSS rates in patients without distant metastasis at
presentation were significantly higher than those in patients
with metastasis (Figure 1B). The median survival of all
patients and patients without distant metastasis at presenta-
tion were undefined. For all patients, there was no signifi-
cant difference in CSS between the renal vein thrombus
group and the IVC thrombus group (Figure 1C); however,
there was a significant difference in CSS between the
patients with N1 and N0/x (Figure 1D). Corresponding
Figure 1 Kaplan-Meier cancer-specific survival in patients with RCC and venous tumor thrombus. (A) Overall patients; (B) presence of
metastasis in overall patients (M0 versus M1); (C) the thrombus level in overall patients (renal vein versus IVC); (D) presence of lymph node
invasion in overall patients (N0 or Nx versus N1); (E) tumor grade in patients without distant metastasis (G1–G2 versus G3–G4); (F) presence of
perinephric fat invasion in patients without distant metastasis (invasion versus non-invasion).
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metastasis depending on the presence of perinephric
fat invasion and tumor grade are shown in Figure 1E,F.
Considering the above two factors, there were statistically
significant differences in CSS.
In terms of several prognostic factors, the following
were significantly associated with CSS in all patients on
univariate analysis: clinical symptoms, ECOG-PS, tumor
grade, T stage, lymph node invasion, distant metastasis
at presentation, perinephric fat invasion, and invasion of
IVC wall. Among these significant prognostic factors,
multivariate Cox regression analysis showed that lymph
node invasion, distant metastasis at presentation, and
invasion of IVC wall were the independent prognostic
factors for CSS in all patients (Table 2). The data of
patients without distant metastasis at presentation
were analyzed separately; univariate analysis showed that
ECOG-PS, tumor grade, T stage, lymph node invasion,
perinephric fat invasion, and invasion of IVC wall were
statistically significant predictors for CSS. Multivariate
Cox regression analysis still showed that tumor grade,
lymph node invasion, and perinephric fat invasion were
the independent factors for predicting CSS in patients
without distant metastasis at presentation (Table 2).
Discussion
The only possible cure for renal cell carcinoma complicated
by tumor thrombus is surgery. With advances in surgical
techniques and instruments, the surgical indications forTable 2 Univariate and multivariate Cox proportional hazard
All patients
Univariate Multivaria
HR (95% CI) P value HR (95%
Age, years (<60 vs ≥60) 0.69(0.31–1.51) 0.35
Gender (male vs female) 0.58(0.26–1.29) 0.18
Laterality (left vs right) 1.43(0.64–3.18) 0.38
Clinical symptom(yes vs no) 3.14(1.25–7.90) 0.018 1.05(0.35–
Tumor size, cm (<7 vs ≥7) 0.60(0.25–1.46) 0.26
ECOG-PS (2–3 vs 0–1) 6.32(2.86–13.9) 0.000 1.22(0.30–
Histological type (clear vs others) 0.71(0.44–2.15) 0.24
Tumor grade (G3–G4 vs G1–G2) 5.41(2.01–14.6) 0.001 2.44(0.74–
T stage (T3c–T4 vs T3a–T3b) 7.29(3.17–16.8) 0.000 4.17(0.85–
N stage (N1 vs N0 or Nx) 13.9(5.45–35.7) 0.000 5.44(1.50–
M stage (M1 vs M0) 16.0(6.34–40.4) 0.000 5.12(1.29–
Perinephric fat invasion (yes vs no) 3.99(1.76–9.05) 0.001 1.48(0.49–
Renal pelvis invasion (yes vs no) 1.15(0.42–3.10) 0.79
Thrombus level (I–III vs 0) 1.68(0.76–3.68) 0.197
Invasion of IVC wall (yes vs no) 6.16(2.62–14.5) 0.000 4.81(1.02–
Neoadjuvant-molecular-targeted
therapy (yes vs no)
0.27(0.0–251.3) 0.52RCC complicated by tumor thrombus have been widened
and, meanwhile, surgical safety has been improved. The use
of laparoscopic and robot-assisted radical nephrectomy and
thrombectomy has also been reported [14]. Nevertheless,
because of the relatively high incidence of perioperative
complications and mortality, the surgical treatment of RCC
complicated by tumor thrombus remains challenging.
Proactive surgical treatments may improve the prognosis
and survival of patients. Adam et al. analyzed 390 patients
with tumor thrombus who did not undergo surgical treat-
ment and found their median and 1-year disease-specific
survival to be only 5 months and 29%, respectively, which
were significantly poorer outcomes than the figures of those
who underwent surgical treatment [15]. Another study
showed the median survival to be 60 months in patients
with RCC and VTT who underwent surgery and 8.2 months
in those who did not undergo surgery, and the 5-year
overall survival rates to be 54% and 0%, respectively [16].
However, it is still controversial as to whether patients with
metastasis should be treated surgically. It was previously
recommended that patients with IVC thrombus and distant
metastasis should not undergo highly traumatic surgery,
because these patients will not survive for long periods
[17]. On the other hand, some other studies have shown
that, while surgery may not achieve radical cure in patients
with metastasis, it usually helped relieve clinical symptoms
and improve the quality of life in patients. Moreover,
cytoreductive surgery plus interferon can prolong the
survival time of patients [18,19]. With the advent ofanalyses for cancer-specific survival
Patients without distant metastasis
te Univariate Multivariate




3.11) 0.93 1.72(0.61–4.86) 0.31
0.64(0.22–1.90) 0.42
4.98) 0.78 4.90(1.73–13.9) 0.003 2.43(0.89–8.67) 0.062
0.72(0.24–2.11) 0.55
8.05) 0.14 4.15(1.30–13.3) 0.016 4.18(1.43–12.9) 0.010
20.3) 0.78 6.05(1.96–18.7) 0.002 3.74(0.77–11.2) 0.612
19.7) 0.010 11.0(3.60–33.9) 0.000 6.74(1.39–32.7) 0.018
20.3) 0.020 - -
4.44) 0.48 3.01(1.09–8.31) 0.034 4.92(1.29–18.7) 0.019
2.02(0.71–5.75) 0.19
1.09(0.39–3.08) 0.87
12.1) 0.048 5.10(1.39–18.8) 0.014 1.61(0.59–16.1) 0.073
- -
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treatment and targeted therapy may improve the long-term
survival of patients. Therefore, we believe that proactive
surgical treatment is a rational choice for patients with
RCC and VTT if their physical status permits.
In the present study, the 1-, 3-, and 5-year CSS rates
were 93.0%, 70.9%, and 58.1%, respectively, in all these
patients, and were 95.3%, 82.6%, and 68.6%, respectively,
in those without metastasis on diagnosis of the cancer.
These figures were better than those reported previously
[3,9,20]. Such differences may arise from the fact that
more patients with renal venous tumor thrombus only
were included in our study, and the proportion of
patients who underwent surgery within the past 3 years was
relatively high in the present study. With improvements in
surgical techniques and perioperative management, as well
as the advent of targeted drugs, the overall survival of
patients with RCC and VTT has increased in recent years.
Additionally, 71 of the patients included in this study
(82.6%) received cytokine therapy. Whether cytokine
therapy played a role, or whether Chinese patients
responded to cytokines better than did non-Chinese
people, is yet to be investigated. Lymph node invasion,
distant metastasis, and IVC wall invasion were suggested
as independent predictors for CSS and overall survival
(OS) [3,16,21,22], and these factors predicted a poor
prognosis. This is basically in agreement with the results
of the present study (Table 2). Meanwhile, the present study
showed that, in the presence or absence of metastasis on
diagnosis of the cancer, lymph node invasion correlated
significantly with a poor prognosis. In the case of caval vein
wall invasion found intraoperatively, complete resection of
the invaded caval vein wall prolonged the survival time
significantly; if necessary, the IVC wall can be repaired
using a graft to prevent IVC stenosis [23]. For non-
metastasis patients, multivariate analysis indicated the
tumor grade and perinephric fat invasion to be an
independent predictor of a poor prognosis in Chinese
patients with RCC and VTT. Obviously, a higher patho-
logical grade usually suggests a more malignant and pro-
gressive tumor. Some other studies also showed a poorer
prognosis in patients with G3 or G4 tumors than in those
with G1 or G2 tumors [22,24]. More frequent postopera-
tive reexamination and follow-up should be considered for
patients with tumors of higher grades. Perinephric fat
invasion usually suggests a greater invasiveness of tumor.
Although some studies have not shown perinephric fat
invasion to be an independent prognostic predictor [9,22],
two multicenter, large-scale studies have demonstrated that
perinephric fat invasion correlated significantly with a poor
prognosis and was an independent prognostic predictor for
CSS in all patients [6,25]. The present study suggested
perinephric fat invasion to be an independent prognostic
predictor in Chinese patients with RCC and VTT butwithout metastasis; however, perinephric fat invasion was a
statistically significant predictor for CSS of all patients in
univariate but not in multivariate analysis (Table 2).
Whether the level of VTT is a prognosis predictor
remains controversial. The present study did not show
significant differences in CSS between the renal vein
group and the IVC group. Some other studies have made
similar findings to ours, revealing no significant correlation
between the level of tumor thrombus and prognosis
[3,26,27]. Moreover, according to the 2002 TNM classifica-
tion, tumor thrombus invasion of the renal vein and IVC is
classified as T3b. On the contrary, many studies have
shown that the prognosis was significantly better in patients
with tumor thrombus invasion of the renal vein alone than
in those with tumor thrombus invasion of the IVC [28,29].
Therefore, the classification of tumor thrombus invasion of
the renal vein has been changed from T3b to T3a accord-
ing to the 2009 TNM classification. Wagner et al. analyzed
the data of 1,192 patients with venous tumor thrombus
from 13 European centers retrospectively and found that
the overall survival time was significantly longer in patients
with tumor thrombus invasion of the renal vein alone than
in those with tumor thrombus invasion of the IVC, but the
level of tumor thrombus in the IVC did not significantly
predict long-term OS [30]. The patients included in this
study did not have level IV tumor thrombus. Moreover,
due to economic considerations, 9 of the 12 patients with
postoperative relapse who received targeted therapy were
preoperatively complicated with IVC tumor thrombus.
These may partly explain why CSS was not significantly
poorer in the IVC group than the renal vein group in our
study. Nevertheless, the surgical risk and the incidence of
perioperative complications were significantly higher in
patients with tumor thrombus invasion of the IVC than in
those with tumor thrombus invasion of renal vein only.
The pre- and post-operative use of molecular-targeted
therapy regimens remains controversial in patients with
RCC and VTT. In our study, two patients received
preoperative neoadjuvant therapy and lowered level IV
tumor thrombus to level III and, subsequently, under-
went radical nephrectomy and tumor thrombectomy.
On the other hand, in some patients, targeted therapy did
not lead to changes in tumor thrombus and metastatic
lesions, and the condition progressed and surgical
treatment became impossible. These patients were not
included in the present study. To date, studies on
molecular-targeted therapy have been carried out
mainly in small numbers of patients with RCC and VTT.
Nicholas et al. reported 25 patients with RCC and IVC
tumor thrombus who received molecular-targeted drugs.
Eleven patients (44%) were found with tumor thrombus
length shrinkage and only three patients (12%) with
lowering of the thrombus level. Among the patients
with tumor thrombus length shrinkage, only one case
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approach. On the other hand, seven patients suffered
from tumor thrombus prolongation [31]. Therefore,
for patients with RCC and VTT, neoadjuvant-targeted
molecular therapies should be selected with caution.
Meanwhile, more prospective studies, and more reliable
molecular markers, are required to be discovered to help
decide who will benefit from molecular-targeted therapy.
The present study bears some limitations. First of all,
this is a single-center, retrospective study based on a
small-sample size. Secondly, the surgical cases spanned a
decade, and different surgeons were involved, which
resulted in heterogeneity of the case data and treatments.
Besides surgery, molecular-targeted therapy may signifi-
cantly affect the survival of patients with RCC and VTT.
All these may lead to statistical biases. Nevertheless, the
present study is a long-term follow-up study with the
largest sample size of Chinese patients with RCC and VTT.
By undertaking more Asian multicenter studies, we hope to
improve the therapeutic efficacy of the treatment of renal
cell carcinoma in Asian patients.
Conclusions
The present study showed that the tumor prognosis
was similar in Chinese patients with RCC and VTT
to patients in other countries. Proactive surgical treatment
may relieve clinical symptoms and benefit patient survival.
Consistent with other studies, the present study showed
distant metastasis, lymph node invasion, and IVC wall
invasion to be independent prognostic factors. In addition,
for Chinese non-metastatic patients, perinephric fat inva-
sion and pathological grade correlated significantly with
tumor prognosis. The advent of the era of molecular-
targeted therapy brings a brighter future for patients with
RCC and VTT. More multicenter, prospective studies
are needed to evaluate the therapeutic efficacy of these
therapies.
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